Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
Gancliclovir is an IV drug that has been shown to decrease the chances of hearing loss in infants with congenitgal cytomegalovirus (CMV). Since CMV-assocaitged hearing loss often emerges after infancy, there is an unmet need for a treatment option for the toddler population. Valganciclovir is the oral form of ganciclovir and we would like to see if giving toddlers with hearing loss and congenital CMV valganciclovir for 6 weeks will stabilize hearing loss.
Who may be Eligible
Ages 1 month through 3 years old; diagnosed with sensorineural hearing loss (SNHL); diagnosed with CMV